TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03976154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Catheter Fixation Techniques
Description: All thoracic epidurals will be placed by a regional anesthesia resident or fellow under the direct supervision of an attending anesthesiologist using a standard epidural kit and in the paramedian approach.~Epidural placement will occur preoperatively in the same manner as our current practice criterion. There will be no difference in placement of the epidural catheter between the control groups and the treatment group. After placement, catheters will be secured with either Dermabond, Mastisol, or a Grip-Lok fixation bandage, all with overlying Tegaderms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural Catheter Fixation Techniques
Description: All thoracic epidurals will be placed by a regional anesthesia resident or fellow under the direct supervision of an attending anesthesiologist using a standard epidural kit and in the paramedian approach.~Epidural placement will occur preoperatively in the same manner as our current practice criterion. There will be no difference in placement of the epidural catheter between the control groups and the treatment group. After placement, catheters will be secured with either Dermabond, Mastisol, or a Grip-Lok fixation bandage, all with overlying Tegaderms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural Catheter Fixation Techniques
Description: All thoracic epidurals will be placed by a regional anesthesia resident or fellow under the direct supervision of an attending anesthesiologist using a standard epidural kit and in the paramedian approach.~Epidural placement will occur preoperatively in the same manner as our current practice criterion. There will be no difference in placement of the epidural catheter between the control groups and the treatment group. After placement, catheters will be secured with either Dermabond, Mastisol, or a Grip-Lok fixation bandage, all with overlying Tegaderms.
Study: NCT04288349

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perineal block with usage of one of solutions
Description: Perineal block using solution of ropivocaine and epinephrine for the first group was performed. Anococcygeal ligament is infiltrated with 10 ml of the solution after the intracutaneous infiltration in 2 cm from the anus. Ten ml of the solution is injected in ischiorectal fat on each side. The needle is orienteered at the angle of 45 degrees cranially and laterally, and to the surface what allows the surgeon to anesthetize the deep branches of the pudendal nerve. In addition, 10 ml of solution is injected transdermal on the front edge of the anus with further subcutaneous infiltration on each side of the anus to provide anesthesia to the nerve branches laying more superficial. The total amount of the injected solution is 50 ml.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: perineal block with usage of one of solutions
Description: Perineal block using solution of ropivocaine and epinephrine for the first group was performed. Anococcygeal ligament is infiltrated with 10 ml of the solution after the intracutaneous infiltration in 2 cm from the anus. Ten ml of the solution is injected in ischiorectal fat on each side. The needle is orienteered at the angle of 45 degrees cranially and laterally, and to the surface what allows the surgeon to anesthetize the deep branches of the pudendal nerve. In addition, 10 ml of solution is injected transdermal on the front edge of the anus with further subcutaneous infiltration on each side of the anus to provide anesthesia to the nerve branches laying more superficial. The total amount of the injected solution is 50 ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine + ropivacaine +saline
Description: epinephrine + ropivacaine +saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: epinephrine + saline
Description: epinephrine + saline
Study: NCT02000778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC17
Study: NCT02909933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin and liraglutide
Study: NCT04175314

Intervention type: OTHER
Intervention: Clinical examination of gingival tissues
Description: Measure of the periodontal recession

Intervention type: OTHER
Intervention: Clinical examination of gingival tissues
Description: Measure of the periodontal recession
Study: NCT05321849

Intervention type: OTHER
Intervention: Echocardiography guide
Description: Patients with PDA are percutaneously closed with echocardiography guide, without fluoroscopy like classical procedures
Study: NCT04216888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Intranasal administration of 40mg ketamine hydrochloride using an intranasal mucosal atomization device
Study: NCT01186822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Flute
Description: Used twice daily
Study: NCT00891553

Intervention type: PROCEDURE
Intervention: DXA
Description: CR9112792 is a follow-up study of CR9108963, in which the effects of ronacaleret (100mg, 200mg, 300mg, 400mg) on bone mineral density (BMD), safety and tolerability were evaluated in comparison with placebo and 2 active comparators, alendronate and teriparatide. In this study we will follow-up subjects between 6 and 12 months after they discontinued treatment with placebo or ronacaleret (200mg, 300mg, 400mg) to evaluate the potential for mineralization of bone following cessation of ronacaleret therapy, evaluating lumbar spine and hip BMD by DXA. There is no administration of drug in this study.

Intervention type: PROCEDURE
Intervention: DXA
Description: CR9112792 is a follow-up study of CR9108963, in which the effects of ronacaleret (100mg, 200mg, 300mg, 400mg) on bone mineral density (BMD), safety and tolerability were evaluated in comparison with placebo and 2 active comparators, alendronate and teriparatide. In this study we will follow-up subjects between 6 and 12 months after they discontinued treatment with placebo or ronacaleret (200mg, 300mg, 400mg) to evaluate the potential for mineralization of bone following cessation of ronacaleret therapy, evaluating lumbar spine and hip BMD by DXA. There is no administration of drug in this study.
Study: NCT03784820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UNITE
Description: UNITE includes three stages: early treatment (psychoeducation and understanding the couple's experience of BED within the relationship); mid-treatment (effective communication, interpersonal problem-solving, and emotion regulation skills), and late treatment (relapse prevention). Additional relevant topics may be covered including body image, weight stigma, weight and health concerns, and intimacy and sexuality issues.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-E
Description: CBT-E includes four stages: an introductory stage (psychoeducation, normalization of eating patterns, and symptom self-monitoring); a second, brief stage (review progress and formulate plans for the subsequent treatment phase); a third stage (elimination of dieting, reducing shape checking and avoidance behaviors, educating about mood tolerance, and targeting overevaluation of shape and weight); and the fourth stage (maintaining progress and minimizing relapse risk).
Study: NCT02227797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: 6 mg/kg to 12 mg/kg IV/PO every 12 hours depending on patient age and dose toleration of prior patients
Study: NCT00847522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein
Description: Fluorescein is an orange-red powdered compound, designated by the formula C20H12O5, which exhibits intense greenish-yellow fluorescence in alkaline solution. It has been used extensively in surgery and medicine for decades for diagnostic purposes. Topical fluorescein is routinely used in ophthalmology to assess corneal lesions. Intravenous fluorescein is used in vascular surgery to measure vascular perfusion and in skin and melanoma surgery to assess the viability of skin flaps.
Study: NCT00574418

Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared Radiation (5μm to 20μm wavelength)
Description: Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes during each session.
Study: NCT02762188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genotype analysis
Description: After signing informed consent, a blood sample is taken and DNA extracted according to standard procedures. The samples are genotyped with the Mass Array iPlex Gold. Processing of the data is done using the previously described protocol by Lambrechts and co.~Statistical analysis will be done to evaluate the association between the different genetic variants and the clinical outcomes collected during the standard of care follow-up for ARMD.
Study: NCT01476605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy
Description: PrT-D solution is 4 mL 50% dextrose, 3 mL normal saline, and 2 mL 2% lidocaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PrT-DMS
Description: PrT-DMS. 1.0 mL 5% morrhuate sodium + 1.5 mL 50% dextrose, 1 mL 2% lidocaine and 3.5 mL normal saline.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma injection
Description: Platelet rich plasma injection therapy (PRP) uses components of autologous blood to promote healing in chronically diseased joint tissues.
Study: NCT05078177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: All patients receive AHSCT with RIC (Cyclophosphamide, Antithymocyte globulin/Rituximab). After resolution of cytopenia (approximately from about D+12 to D+14 AHSCT), patients will receive intrathecal Rituximab.
Study: NCT03313947

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: The following 6 questions will be asked during the preoperative visit:~1. While sleeping, does your child snore more than half the time?~2. While sleeping, does your child always snore?~3. Have you ever seen your child stop breathing during the night?~4. Does your child occasionally wet the bed?~5. Did your child stop growing at a normal rate at any time since birth?~6. Is your child overweight
Study: NCT00450229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diindolylmethane
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diindolylmethane
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02227992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVARREST™ Sealant Matrix
Description: EVARREST® Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SURGICEL®
Description: SURGICEL® Absorbable Hemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
Study: NCT01371708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DVS SR
Description: Subjects will receive a flexible-dose of 20, 25, 35, or 50 mg/day as prescribed by the investigator
Study: NCT03910322

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bif195
Description: Two different doses of the bacterial strain Bif195 is compared to placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bif195
Description: Two different doses of the bacterial strain Bif195 is compared to placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01508663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus Eluting Stent or Zotalolimus Eluting Stent
Description: Everolimus Eluting Stent(Xience V, Xience prime) Zotalolimus Eluting Stent(Endeavor-resolute, Resolute Integrity)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
Description: one or two anti-platelet agents, beta-blockers, calcium channel blockers, nitrates, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), and statin
Study: NCT03138642

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT
Description: All the patients receive extended resection to primary tumor and post-surgery RT. The patients are prescribed a EQD2 of 70-77Gy to GTV (residual tumor), 65-70Gy to CTV1(high-risk regions including tumor bed and gross macroscopic residual tumor), 50-55Gy to CTV2(low-risk regions) using Intensity-modulated radiotherapy (IMRT)
Study: NCT02523690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Description: 10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral or enteral, single dose. Oral or enteral, single dose two days later
Study: NCT00833378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag
Description: Eltrombopag 100 mg single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: Lopinavir/Ritonavir 400/100 mg oral dose given twice a day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag and Lopinavir/Ritonavir
Description: Elrombopag 100 mg single oral dose and Lopinavir/Ritonavir 400/100 mg oral dose given in the AM and PM
Study: NCT04529005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: If intraoperative or postoperative hypotension occurs (e.g. SBP \< 120 mmHg) and the attending surgeon and/or attending anesthesiologist deems vasopressor therapy to be necessary, angiotensin II (Giapreza) will be the first vasopressor used for management.
Study: NCT00987662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Treatment with irbesartan 300mg for 4 weeks. IF ABP\>135/85 mmHg add hydrochlorothiazide 12.5 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Treatment with amlodipine 10 mg for 4 weeks. If ABP\>135/85 mmHg add hydrochlorothiazide 12.5 mg
Study: NCT03354468

Intervention type: BEHAVIORAL
Intervention: fall prevention program
Description: fall prevention program in orthopedic department, consisting of 1) Seven examples of risk factors which might cause falls (diseases and medications, movement, cognitive behavior, vision, continence, nutrition, and the room and surroundings), 2) Methods to detect the risk factors, and 3) Measures to avoid falls or protect the patient in case of a fall.

Intervention type: BEHAVIORAL
Intervention: fall prevention program
Description: fall prevention program in orthopedic department, consisting of 1) Seven examples of risk factors which might cause falls (diseases and medications, movement, cognitive behavior, vision, continence, nutrition, and the room and surroundings), 2) Methods to detect the risk factors, and 3) Measures to avoid falls or protect the patient in case of a fall.
Study: NCT04088539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD advice
Description: Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-based health education
Description: Educational videos on smoking and health will be developed to improve the knowledge of CSD smokers. The videos aim to raise their awareness on these important health topics and acquire effective cessation methods. The effectiveness of the educational videos will be evaluated by pre- and post-tests through a self-administered survey that assess the changes in knowledge related to smoking hazards, benefits of quitting, and methods to quit smoking.
Study: NCT00656747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Subjects will be randomised to moxifloxacin 400 mg PO OD (5 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin clavulanic acid
Description: Subjects will be randomised to amoxicillin-clavulanic acid 875/125 mg PO BID (7 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.
Study: NCT02803281

Intervention type: OTHER
Intervention: Frailty Assessment
Description: Various physiologic and frailty assessment tests

Intervention type: OTHER
Intervention: Frailty Assessment
Description: Various physiologic and frailty assessment tests
Study: NCT01077518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab
Description: Ofatumumab was a liquid concentrate solution for infusion presented in glass vials containing 50 mL of solution at a concentration of 20 mg/mL to provide 1000 mg per vial. The ofatumumab infusions were prepared in 1000 mL sterile, pyrogen-free 0.9% NaCl to yield a 1 mg/mL ofatumumab concentration infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab was a liquid concentrate solution for infusion presented in glass vials containing 50 mL of solution at a concentration of 20 mg/mL to provide 1000 mg per vial. The ofatumumab infusions were prepared in 1000 mL sterile, pyrogen-free 0.9% NaCl to yield a 1 mg/mL ofatumumab concentration infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine infusion
Description: Bendamustine 100 mg/vial, injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab and Bendamustine infusions (Arm A)
Description: Up to 8 cycles of Bendamustine (90 mg/m2 Days 1 and 2, every 21 days) given in combination with 12 doses of ofatumumab (1000 mg). Ofatumumab will be given on day 1 of each cycle of bendamustine as long as patients in Arm A receive bendamustine. Once patients in Arm A complete bendamustine therapy, the remaining doses of ofatumumab will be given monthly until all 12 doses are completed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine infusion (Arm B)
Description: Bendamustine (120 mg/m2 Days 1 and 2, every 21 days, up to 8 cycles).
Study: NCT02880943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XOFIGO
Description: XOFIGO® will be administered intravenously as a bolus injection every 4 weeks with a maximum of 6 administrations per patient.~Four dose levels are available for evaluation : 27.5 kBq/kg, 55 kBq/kg, 88 kBq/kg and 110 kBq/kg.~Starting dose for phase I will be 55 kBq/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XOFIGO
Description: XOFIGO® will be administered intravenously as a bolus injection every 4 weeks with a maximum of 6 administrations per patient.~Four dose levels are available for evaluation : 27.5 kBq/kg, 55 kBq/kg, 88 kBq/kg and 110 kBq/kg.~Starting dose for phase I will be 55 kBq/kg.
Study: NCT01947699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Study: NCT02304081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: competitive inhibitor of human dipepitdylpeptidase (DPP)-IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Saxagliptin
Study: NCT00475228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel IUD
Description: intrauterine insertion for arm 1 immediately after D\&E procedure and for arm 2 at 3-6 weeks post-procedurem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD
Description: intrauterine insertion for arm 1 immediately after D\&E procedure and for arm 2 at 3-6 weeks post-procedurem
Study: NCT02339870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial Support for Caregiver
Description: Complete expressive disclosure writing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial Support for Caregiver
Description: Complete benefit finding writing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Complete writing on an emotionally neutral topic
Study: NCT04925869

Intervention type: OTHER
Intervention: Observational study
Description: Observational study

Intervention type: OTHER
Intervention: Observational study
Description: Observational study

Intervention type: OTHER
Intervention: Observational study
Description: Observational study